Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

4

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Aminopeptidase activity

4

Catalase

4

Cyclooxygenase-1

4

Cyclooxygenase-2

4

UDP-glucuronosyltransferase 1-9

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

6

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1982

4

1985

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Osteoarthritis

4

Rheumatoid arthritis

4

Intraoperative miosis

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

4

Preventing

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

4

Janssen

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

6

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

6

FDA UNII

6

PUBCHEM

6

EPA CompTox

5

EVMPD

4

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

MUSCULO-SKELETAL SYSTEM

2

SENSORY ORGANS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

2

OPHTHALMOLOGICALS

1

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

2

ANTIINFLAMMATORY AGENTS

1

TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinflammatory agents, non-steroids

1

Antiinflammatory preparations, non-steroids for topical use

1

Oxicams

1

Propionic acid derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

4

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 6 of 6 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

PIROXICAM

13T4O6VMAM

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

UDP-glucuronosyltransferase 1-9

Aminopeptidase activity

Cyclooxygenase-1

platelet aggregation

Cyclooxygenase-2

Conditions:

Rheumatoid arthritis

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxic...

am works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.

SUPROFEN

988GU2F9PE

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1985

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Prostaglandin G/H synthase 1

Prostaglandin G/H synthase 2

Conditions:

Intraoperative miosis

Suprafen is a dual inhibitor of COX-1 and COX-2, which was used for the inhibition of intraoperative miosis. Suprafen was marketed under the name Profenal, however, it is no longer available in the USA.

PIROXICAM POTASSIUM

S5XT2DB4P6

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

UDP-glucuronosyltransferase 1-9

Aminopeptidase activity

Cyclooxygenase-1

platelet aggregation

Cyclooxygenase-2

Conditions:

Rheumatoid arthritis

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxic...

am works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.

PIROXICAM MONOHYDRATE

28MQO4N66D

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

UDP-glucuronosyltransferase 1-9

Aminopeptidase activity

Cyclooxygenase-1

platelet aggregation

Cyclooxygenase-2

Conditions:

Rheumatoid arthritis

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxic...

am works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.

PIROXICAM OLAMINE

T4O2MP4507

Export Data
Search for Structure

Status:

US Approved Rx (2017)

First approved in 1982

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

UDP-glucuronosyltransferase 1-9

Aminopeptidase activity

Cyclooxygenase-1

platelet aggregation

Cyclooxygenase-2

Conditions:

Rheumatoid arthritis

Piroxicam is in a class of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs). It was originally brought to market by Pfizer under the tradename Feldene in 1980, became generic in 1992, and is marketed worldwide under many brandnames. Piroxic...

am works by reducing hormones that cause inflammation and pain in the body. Piroxicam is used to reduce the pain, inflammation, and stiffness caused by rheumatoid arthritis and osteoarthritis. The antiinflammatory effect of Piroxicam may result from the reversible inhibition of cyclooxygenase, causing the peripheral inhibition of prostaglandin synthesis. The prostaglandins are produced by an enzyme called Cox-1. Piroxicam blocks the Cox-1 enzyme, resulting into the disruption of production of prostaglandins. Piroxicam also inhibits the migration of leukocytes into sites of inflammation and prevents the formation of thromboxane A2, an aggregating agent, by the platelets. Piroxicam is used for treatment of osteoarthritis and rheumatoid arthritis.

SUPROFEN SODIUM

S8LB9M91ST

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1985

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Prostaglandin G/H synthase 1

Prostaglandin G/H synthase 2

Conditions:

Intraoperative miosis

Suprafen is a dual inhibitor of COX-1 and COX-2, which was used for the inhibition of intraoperative miosis. Suprafen was marketed under the name Profenal, however, it is no longer available in the USA.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1